Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Ngm Biopharmaceuticals Inc (NGM)

Ngm Biopharmaceuticals Inc (NGM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,370,429
  • Shares Outstanding, K 77,338
  • Annual Sales, $ 87,370 K
  • Annual Income, $ -102,490 K
  • 60-Month Beta 1.81
  • Price/Sales 15.95
  • Price/Cash Flow N/A
  • Price/Book 3.94
Trade NGM with:

Options Overview Details

View History
  • Implied Volatility 96.79%
  • Historical Volatility 40.92%
  • IV Percentile 35%
  • IV Rank 16.20%
  • IV High 191.41% on 09/07/21
  • IV Low 78.49% on 07/20/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 37
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 0
  • Open Int (30-Day) 29

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate -0.37
  • Number of Estimates 4
  • High Estimate -0.30
  • Low Estimate -0.39
  • Prior Year -0.40
  • Growth Rate Est. (year over year) +7.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.05 +4.49%
on 11/30/21
21.63 -17.64%
on 11/05/21
-1.32 (-6.92%)
since 11/02/21
3-Month
17.05 +4.49%
on 11/30/21
27.25 -34.62%
on 09/13/21
-4.02 (-18.43%)
since 09/02/21
52-Week
14.90 +19.56%
on 05/28/21
32.12 -44.54%
on 03/17/21
-6.03 (-25.30%)
since 12/02/20

Most Recent Stories

More News
NGM Bio to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on...

NGM : 17.99 (+1.52%)
NGM Biopharmaceuticals (NGM) Reports Q3 Loss, Lags Revenue Estimates

NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 2.63% and -1.74%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?...

NGM : 17.99 (+1.52%)
NGM Biopharmaceuticals: Q3 Earnings Snapshot

SOUTH SAN FRANCISCO, Calif. (AP) _ NGM Biopharmaceuticals Inc. (NGM) on Thursday reported a loss of $28.9 million in its third quarter.

NGM : 17.99 (+1.52%)
NGM Biopharmaceuticals (NGM) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

NGM Biopharmaceuticals (NGM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NGM : 17.99 (+1.52%)
NGM Bio Presents Preliminary Findings from Ongoing Phase 1a/1b Dose Escalation Study of NGM120 in Patients with Advanced Solid Tumors at the ESMO Virtual Congress 2021

SOUTH SAN FRANCISCO, Calif., Sept. 16, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics...

NGM : 17.99 (+1.52%)
NGM Bio Discloses Fourth Oncology Development Candidate, NGM831, an ILT3 Antagonist Antibody, Coinciding with Publication in Cancer Immunology Research

SOUTH SAN FRANCISCO, Calif., Aug. 23, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics...

NGM : 17.99 (+1.52%)
NGM Bio Provides Business Highlights and Reports Second Quarter 2021 Financial Results

SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics...

NGM : 17.99 (+1.52%)
NGM Announces Completion of Enrollment in Phase 2 CATALINA Study of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration

SOUTH SAN FRANCISCO, Calif., July 22, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics...

NGM : 17.99 (+1.52%)
NGM Bio Announces Initiation of Phase 1/2 Clinical Study of NGM707 for the Treatment of Advanced Solid Tumors

--NGM707, a ILT2/ILT4 dual antagonistic antibody, is engineered to reverse myeloid suppression with the goal of improving patient immune responses to tumors--

NGM : 17.99 (+1.52%)
NGM Amends Collaboration with Merck to Focus Primarily on Advancing Novel Medicines for Retinal and Cardiovascular and Metabolic (CVM) Diseases

SOUTH SAN FRANCISCO, Calif., July 01, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) today announced that the company has entered into an amended and restated agreement with Merck, known...

NGM : 17.99 (+1.52%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

NGM Biopharmaceuticals Inc. is focused on developing novel therapeutics for underlying cardio-metabolic, liver, oncologic and ophthalmic diseases. The company's product pipeline consists of NGM282, NGM313, NGM120, NGM217, NGM621, NGM386 and NGM395 which are in clinical stage. NGM Biopharmaceuticals Inc....

See More

Key Turning Points

3rd Resistance Point 19.30
2nd Resistance Point 18.88
1st Resistance Point 18.30
Last Price 17.99
1st Support Level 17.30
2nd Support Level 16.88
3rd Support Level 16.30

See More

52-Week High 32.12
Fibonacci 61.8% 25.54
Fibonacci 50% 23.51
Fibonacci 38.2% 21.48
Last Price 17.99
52-Week Low 14.90

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar